GlassScriptPhysician profile
Timothy William Cox
NPI 1265000574
$1,061.64
in general payments reported to CMS, 2019-2025
18 companies · $802 in 2025
The $802 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.20 · 2024: $243 · 2025: $802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,045.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $187.58 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $154.48 | 2024-2025 | Zepbound, Mounjaro |
| Amgen INC. | $118.32 | 2024-2025 | Evenity, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.18 | 2025 | Jardiance |
| Radius Health, INC. | $106.36 | 2025 | Tymlos |
| Abbvie INC. | $65.71 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $61.26 | 2024-2025 | Farxiga, Breztri |
| Phathom Pharmaceuticals, INC. | $59.31 | 2024-2025 | Voquezna |
| Medtronic, INC. | $37.19 | 2025 | Inceptiv |
| Dexcom, INC. | $22.34 | 2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $21.96 | 2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $20.87 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.41 | 2025 | Caplyta |
| Neurocrine Biosciences, INC. | $16.20 | 2021 | |
| Axsome Therapeutics, INC. | $14.38 | 2025 | Auvelity |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $13.95 | 2025 | Spravato |
| Kowa Pharmaceuticals America, INC. | $13.68 | 2025 | Zoryve |
| Glaxosmithkline, LLC. | $13.46 | 2025 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.